JP7849383B2 - コンジュゲートされたヘプシジン模倣物 - Google Patents
コンジュゲートされたヘプシジン模倣物Info
- Publication number
- JP7849383B2 JP7849383B2 JP2023560496A JP2023560496A JP7849383B2 JP 7849383 B2 JP7849383 B2 JP 7849383B2 JP 2023560496 A JP2023560496 A JP 2023560496A JP 2023560496 A JP2023560496 A JP 2023560496A JP 7849383 B2 JP7849383 B2 JP 7849383B2
- Authority
- JP
- Japan
- Prior art keywords
- lys
- 1peg2
- hepcidin
- ala
- ahx
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Analytical Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026028383A JP2026083122A (ja) | 2021-04-01 | 2026-02-25 | コンジュゲートされたヘプシジン模倣物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163169545P | 2021-04-01 | 2021-04-01 | |
| US63/169,545 | 2021-04-01 | ||
| US202263325328P | 2022-03-30 | 2022-03-30 | |
| US63/325,328 | 2022-03-30 | ||
| PCT/US2022/022817 WO2022212700A2 (en) | 2021-04-01 | 2022-03-31 | Conjugated hepcidin mimetics |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026028383A Division JP2026083122A (ja) | 2021-04-01 | 2026-02-25 | コンジュゲートされたヘプシジン模倣物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024513391A JP2024513391A (ja) | 2024-03-25 |
| JP2024513391A5 JP2024513391A5 (cg-RX-API-DMAC7.html) | 2025-03-06 |
| JP7849383B2 true JP7849383B2 (ja) | 2026-04-21 |
Family
ID=83459967
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023560496A Active JP7849383B2 (ja) | 2021-04-01 | 2022-03-31 | コンジュゲートされたヘプシジン模倣物 |
| JP2026028383A Pending JP2026083122A (ja) | 2021-04-01 | 2026-02-25 | コンジュゲートされたヘプシジン模倣物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026028383A Pending JP2026083122A (ja) | 2021-04-01 | 2026-02-25 | コンジュゲートされたヘプシジン模倣物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240209053A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4314014A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7849383B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022249097A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3214153A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202304952A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022212700A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4091624A1 (en) | 2013-03-15 | 2022-11-23 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| CA2949215C (en) | 2014-05-16 | 2023-03-14 | Protagonist Therapeutics, Inc. | .alpha.4.beta.7 integrin thioether peptide antagonists |
| SG10201810154WA (en) | 2014-07-17 | 2018-12-28 | Protagonist Therapeutics Inc | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| WO2018022937A1 (en) | 2016-07-27 | 2018-02-01 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases |
| WO2019157268A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| MX2022008740A (es) | 2020-01-15 | 2022-09-23 | Janssen Biotech Inc | Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias. |
| AU2021383828A1 (en) | 2020-11-20 | 2023-07-06 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of interleukin-23 receptor |
| KR20240034224A (ko) | 2021-07-14 | 2024-03-13 | 얀센 바이오테크 인코포레이티드 | 인터류킨-23 수용체의 지질화된 펩티드 억제제 |
| EP4472995A4 (en) * | 2022-02-02 | 2025-11-19 | Protagonist Therapeutics Inc | Conjugated hepcidin mimetics |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060008848A1 (en) | 1999-05-18 | 2006-01-12 | Verdine Gregory L | Stabilized compounds having secondary structure motifs |
| US20100036089A1 (en) | 2006-02-17 | 2010-02-11 | Monash University | Methods for the Synthesis of Dicarba Bridges in Organic Compounds |
| US20190002503A1 (en) | 2015-12-30 | 2019-01-03 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002079235A2 (en) * | 2001-03-30 | 2002-10-10 | University Of Copenhagen | Compositions and methods for modulating guanylyl cyclase signaling receptor (gc-c) activity and for treating meniere's disease |
| WO2010065815A2 (en) * | 2008-12-05 | 2010-06-10 | The Regents Of The University Of California | Mini-hepcidin peptides and methods of using thereof |
| SG10201810154WA (en) * | 2014-07-17 | 2018-12-28 | Protagonist Therapeutics Inc | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| WO2019157268A1 (en) * | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
-
2022
- 2022-03-31 EP EP22782209.5A patent/EP4314014A4/en active Pending
- 2022-03-31 CA CA3214153A patent/CA3214153A1/en active Pending
- 2022-03-31 US US18/285,198 patent/US20240209053A1/en active Pending
- 2022-03-31 JP JP2023560496A patent/JP7849383B2/ja active Active
- 2022-03-31 WO PCT/US2022/022817 patent/WO2022212700A2/en not_active Ceased
- 2022-03-31 AU AU2022249097A patent/AU2022249097A1/en active Pending
- 2022-04-01 TW TW111112896A patent/TW202304952A/zh unknown
-
2026
- 2026-02-25 JP JP2026028383A patent/JP2026083122A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060008848A1 (en) | 1999-05-18 | 2006-01-12 | Verdine Gregory L | Stabilized compounds having secondary structure motifs |
| US20100036089A1 (en) | 2006-02-17 | 2010-02-11 | Monash University | Methods for the Synthesis of Dicarba Bridges in Organic Compounds |
| US20190002503A1 (en) | 2015-12-30 | 2019-01-03 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022212700A3 (en) | 2022-12-08 |
| CA3214153A1 (en) | 2022-10-06 |
| US20240209053A1 (en) | 2024-06-27 |
| JP2024513391A (ja) | 2024-03-25 |
| EP4314014A2 (en) | 2024-02-07 |
| AU2022249097A1 (en) | 2023-10-12 |
| EP4314014A4 (en) | 2025-03-05 |
| WO2022212700A2 (en) | 2022-10-06 |
| TW202304952A (zh) | 2023-02-01 |
| JP2026083122A (ja) | 2026-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12234300B2 (en) | Conjugated hepcidin mimetics | |
| US11472842B2 (en) | Analogues of hepcidin mimetics with improved in vivo half lives | |
| JP2026048851A (ja) | コンジュゲートされたヘプシジン模倣物 | |
| JP7831841B2 (ja) | コンジュゲートされたヘプシジン模倣物 | |
| JP2026083122A (ja) | コンジュゲートされたヘプシジン模倣物 | |
| JP2024513392A (ja) | コンジュゲートされたヘプシジン模倣物 | |
| WO2022212698A1 (en) | Conjugated hepcidin mimetics | |
| EP4472996A2 (en) | Conjugated hepcidin mimetics | |
| EP4472995A2 (en) | Conjugated hepcidin mimetics | |
| CN117730089A (zh) | 结合型铁调素模拟物 | |
| CN117813313A (zh) | 结合型铁调素模拟物 | |
| CN117136192A (zh) | 缀合的铁调素模拟物 | |
| WO2025226506A1 (en) | Mono- and dual-agonist compounds of human glp1r and gipr for obesity & t2dm | |
| EA053112B1 (ru) | Конъюгированные миметики гепсидина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250226 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250226 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251226 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260225 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260324 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260409 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7849383 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |